Sen. Bernie Sanders. (Photo: Rick Koppstein/ALM Media)

Congressional scrutiny of drug prices continued to heat up on Thursday, with three pharmaceutical executives taking the hot seat before a Senate panel. The CEOs of Merck, Bristol Myers Squibb and Johnson & Johnson faced a barrage of questions from members of the Health, Education, Labor and Pensions committee.

"The overwhelming beneficiary of high drug prices in America is the pharmaceutical industry," committee Chair Bernie Sanders, I-Vt., said. "The United States government does not regulate drug companies. With a few exceptions, the drug companies regulate the United States government."

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Health Care Reform
Cost-Containment
Employee Participation
Employee-Paid
Employer-Paid